| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT07383441 Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer |
Recruitment opened |
| 2026-06-12 | NCT07383441 Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer |
Trial sites expanded: 0 -> 41 locations |
| 2026-06-10 | NCT07466225 HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion |
overall status: "Not Yet Recruiting" → "Active Not Recruiting" |
| 2026-06-10 | NCT07466225 HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion |
date change Primary completion pushed: 2026-06-30 -> 2026-12-30 |
| 2026-06-10 | NCT07466225 HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion |
date change Completion pushed: 2026-08-31 -> 2027-06-30 |
| 2026-06-09 | NCT07405164 Extension Study for Participants in Studies That Include Belzutifan… |
Trial sites expanded: 15 -> 20 locations |
| 2026-06-04 | NCT04164199 Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With… |
Trial completed |
| 2026-06-04 | NCT04164199 Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With… |
date change Primary completion moved earlier: 2026-07 -> 2026-05-23 |
| 2026-06-04 | NCT04164199 Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With… |
date change Completion moved earlier: 2026-07 -> 2026-05-23 |
| 2026-05-29 | NCT04305054 Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational… |
Trial completed |
| 2026-05-28 | NCT04938817 Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With… |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-05-23 | NCT07493668 Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After… |
Recruitment opened |
| 2026-05-16 | NCT04977453 GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in… |
Trial sites expanded: 8 -> 12 locations |
| 2026-05-14 | NCT06110793 A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer |
Enrollment increased: 49 -> 54 participants |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-05-18 | NCT07594015 Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer… | Phase 2 | Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT03486873 | Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who… | Solid Tumors | Recruiting |
| NCT07405164 | Extension Study for Participants in Studies That Include Belzutifan… | Von Hippel-Lindau Disease | Recruiting |
| NCT07383441 | Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer | Advanced Clear Cell Renal Cell Carcinoma | Recruiting |
| NCT02811861 | Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of… | Renal Cell Carcinoma | Active, Not Recruiting |
| NCT07475026 | A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of… | HCC - Hepatocellular Carcinoma | Not Yet Recruiting |
| NCT04039607 | A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced… | Hepatocellular Carcinoma | Active, Not Recruiting |
| NCT05301842 | Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients… | Hepatocellular Carcinoma | Active, Not Recruiting |
| NCT07537946 | Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer | Hepatocellular Carcinoma (HCC) | Not Yet Recruiting |
| NCT04586231 | A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for… | Carcinoma, Renal Cell | Active, Not Recruiting |
| NCT04736706 | A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and… | Carcinoma, Renal Cell | Active, Not Recruiting |
| NCT04770896 | A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone… | Unresectable Hepatocellular Carcinoma | Active, Not Recruiting |
| Phase 2 | |||
| NCT06859684 | Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in… | Intrahepatic Cholangiocarcinoma (Icc) | Recruiting |
| NCT05746208 | Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors | Neuroendocrine Tumors | Recruiting |
| NCT07092514 | Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive… | Thyroid Cancer | Recruiting |
| NCT06669572 | Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten… | Carcinoma, Squamous Cell | Recruiting |
| NCT05064280 | Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC… | Brain Metastases | Recruiting |
| NCT05775159 | Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents… | Hepatocellular Carcinoma | Recruiting |
| NCT07328009 | A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma | Hepato Cellular Carcinoma (HCC) | Recruiting |
| NCT07219459 | Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in… | Unresectable or Metastatic Hepatocellular Carcinoma | Recruiting |
| NCT05327686 | Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the… | Metastatic Renal Cell Carcinoma | Recruiting |
| NCT07014150 | Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for… | Hepatocellular Carcinoma Resectable | Recruiting |
| NCT06266338 | Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem… | Cervix Cancer | Recruiting |
| NCT05903833 | Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or… | Recurrent Vulvar Cancer | Recruiting |
| NCT07571551 | Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell Carcinoma | Clear Cell RCC | Recruiting |
| NCT07594015 | Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer… | Recurrent Endometrial Cancer | Recruiting |